Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

HCW Biologics (HCWB) Debt to Equity (2022 - 2025)

HCW Biologics (HCWB) has disclosed Debt to Equity for 4 consecutive years, with -$3.23 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Debt to Equity fell 407.96% year-over-year to -$3.23, compared with a TTM value of -$3.23 through Sep 2025, down 407.96%, and an annual FY2024 reading of -$0.93, changed N/A over the prior year.
  • Debt to Equity was -$3.23 for Q3 2025 at HCW Biologics, up from -$123.55 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.02 in Q4 2022 and bottomed at -$123.55 in Q2 2025.
  • Average Debt to Equity over 4 years is -$11.64, with a median of -$0.02 recorded in 2024.
  • The sharpest move saw Debt to Equity skyrocketed 570.59% in 2024, then tumbled 627596.89% in 2025.
  • Year by year, Debt to Equity stood at $1.02 in 2022, then plummeted by 99.52% to $0.0 in 2023, then tumbled by 19016.72% to -$0.93 in 2024, then tumbled by 246.36% to -$3.23 in 2025.
  • Business Quant data shows Debt to Equity for HCWB at -$3.23 in Q3 2025, -$123.55 in Q2 2025, and -$0.73 in Q1 2025.